Cell Growth & Differentiation, Vol 6, Issue 11 1447-1455, Copyright © 1995 by American Association of Cancer Research

ARTICLES

Activation of the epidermal growth factor receptor by skin tumor promoters and in skin tumors from SENCAR mice

W Xian, K Kiguchi, A Imamoto, T Rupp, A Zilberstein and J DiGiovanni
Department of Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957, USA.

The present study was designed to further investigate the role of the epidermal growth factor receptor (EGFr) in mouse skin tumor promotion by evaluating the status of the EGFr in tumor promoter-treated mouse epidermis and in mouse skin tumors. Female SENCAR mice received three topical treatments of either the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) or the nonphorbol esters okadaic acid and chrysarobin. Membrane proteins from SENCAR mouse epidermis were isolated 6 h after the last treatment, and the phosphotyrosine content of the EGFr and several potential substrates were examined by Western blot analysis. The results indicated that multiple applications of all three tumor promoters led to an increase in the phosphotyrosine content of the EGFr and also of several lower molecular weight proteins (M(r) approximately 80,000-85,000). Phosphorylation of PLC gamma 1 on tyrosine residues could not be detected in tumor promoter-treated mouse epidermis when the phosphotyrosine content of the EGFr was elevated or in cultured keratinocytes exposed to exogenous EGF. When two tyrosine kinase inhibitors (tyrphostins RG50864 and RG13022) were incorporated into the treatment regimens, the TPA-induced epidermal hyperplasia and cell proliferation were effectively blocked, and the TPA-stimulated EGFr tyrosine phosphorylation was significantly reduced. Examination of the phosphotyrosine content of epidermal membrane proteins isolated from skin papillomas revealed that the EGFr also had elevated phosphotyrosine levels. These results demonstrate that multiple topical treatments with both phorbol ester and nonphorbol ester tumor promoters lead to activation of the EGFr tyrosine kinase in mouse epidermis. In addition, these data suggest that signaling through the EGFr pathway plays an important role in the tumor promotion stage of multistage carcinogenesis in mouse skin.

This article has been cited by other articles:

				S. D'Alessio, L. Gerasi, and F. Blasi uPAR-deficient mouse keratinocytes fail to produce EGFR-dependent laminin-5, affecting migration in vivo and in vitro J. Cell Sci., December 1, 2008; 121(23): 3922 - 3932. [Abstract] [Full Text] [PDF]

				T. Moore, S. Carbajal, L. Beltran, S. N. Perkins, S. Yakar, D. LeRoith, S. D. Hursting, and J. DiGiovanni Reduced Susceptibility to Two-Stage Skin Carcinogenesis in Mice with Low Circulating Insulin-Like Growth Factor I Levels Cancer Res., May 15, 2008; 68(10): 3680 - 3688. [Abstract] [Full Text] [PDF]

				J. Lu, O. Rho, E. Wilker, L. Beltran, and J. DiGiovanni Activation of Epidermal Akt by Diverse Mouse Skin Tumor Promoters Mol. Cancer Res., December 1, 2007; 5(12): 1342 - 1352. [Abstract] [Full Text] [PDF]

				T. Hara, Y. Saito, T. Hirai, K. Nakamura, K. Nakao, M. Katsuki, and K. Chida Deficiency of Protein Kinase C{alpha} in Mice Results in Impairment of Epidermal Hyperplasia and Enhancement of Tumor Formation in Two-Stage Skin Carcinogenesis Cancer Res., August 15, 2005; 65(16): 7356 - 7362. [Abstract] [Full Text] [PDF]

				K. S. Chan, S. Carbajal, K. Kiguchi, J. Clifford, S. Sano, and J. DiGiovanni Epidermal Growth Factor Receptor-Mediated Activation of Stat3 during Multistage Skin Carcinogenesis Cancer Res., April 1, 2004; 64(7): 2382 - 2389. [Abstract] [Full Text] [PDF]

				N. Chen, W.-Y. Ma, Q.-B. She, E. Wu, G. Liu, A. M. Bode, and Z. Dong Transactivation of the Epidermal Growth Factor Receptor Is Involved in 12-O-Tetradecanoylphorbol-13-acetate-induced Signal Transduction J. Biol. Chem., December 7, 2001; 276(50): 46722 - 46728. [Abstract] [Full Text] [PDF]

				C. D. Woodworth, D. Gaiotti, E. Michael, L. Hansen, and M. Nees Targeted Disruption of the Epidermal Growth Factor Receptor Inhibits Development of Papillomas and Carcinomas from Human Papillomavirus-immortalized Keratinocytes Cancer Res., August 1, 2000; 60(16): 4397 - 4402. [Abstract] [Full Text]

				L. A. Hansen, R. L. Woodson II, S. Holbus, K. Strain, Y.-C. Lo, and S. H. Yuspa The Epidermal Growth Factor Receptor Is Required to Maintain the Proliferative Population in the Basal Compartment of Epidermal Tumors Cancer Res., July 1, 2000; 60(13): 3328 - 3332. [Abstract] [Full Text]

				J. Zhao and R. Agarwal Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention Carcinogenesis, November 1, 1999; 20(11): 2101 - 2108. [Abstract] [Full Text] [PDF]

				Q. Li, S. M. Vaingankar, H. M. Green, and M. Martins-Green Activation of the 9E3/cCAF Chemokine by Phorbol Esters Occurs via Multiple Signal Transduction Pathways That Converge to MEK1/ERK2 and Activate the Elk1 Transcription Factor J. Biol. Chem., May 28, 1999; 274(22): 15454 - 15465. [Abstract] [Full Text] [PDF]

				M. Lahiri-Chatterjee, S. K. Katiyar, R. R. Mohan, and R. Agarwal A Flavonoid Antioxidant, Silymarin, Affords Exceptionally High Protection against Tumor Promotion in the SENCAR Mouse Skin Tumorigenesis Model Cancer Res., February 1, 1999; 59(3): 622 - 632. [Abstract] [Full Text] [PDF]

				S. P. Soltoff Related Adhesion Focal Tyrosine Kinase and the Epidermal Growth Factor Receptor Mediate the Stimulation of Mitogen-activated Protein Kinase by the G-protein-coupled P2Y2 Receptor. PHORBOL ESTER OR [Ca2+]i ELEVATION CAN SUBSTITUTE FOR RECEPTOR ACTIVATION J. Biol. Chem., September 4, 1998; 273(36): 23110 - 23117. [Abstract] [Full Text] [PDF]